ImmunAdd Inc.

ImmunAdd Inc. , based in Taipei, Taiwan, specializes in the development of advanced vaccine adjuvants, focusing on enhancing immune responses and stability for improved therapeutic outcomes. Founded in 2022, ImmunAdd Inc. is dedicated to developing novel vaccine adjuvants.

The company was founded by its CEO Dr. Pi‑Hui Liang. ImmunAdd, Inc. specializes in the development of next-generation vaccine adjuvants, particularly its core product, IA-05, a truncated analogue of QS-21.

IA-05 enhances immune responses and improves tolerability and stability when used with various antigens. The company targets biopharmaceutical firms and research institutions globally, focusing on markets in North America, Europe, and Asia, aiming for collaborations that leverage its advanced adjuvant technology for enhanced vaccine formulations. ImmunAdd's revenue generation strategy relies on partnerships with biopharmaceutical companies and research institutions through B2B transactions, where it licenses its proprietary adjuvant technology. This involves upfront licensing fees along with milestone payments or royalties based on future product sales, tailored to each agreement.

The flagship product, IA-05, is central to these collaborations, highlighting the potential for sustained revenue through integration into multiple vaccine platforms. ImmunAdd plans to use the recently raised USD 15. 00 mn from its Series A funding to complete preclinical milestones and advance its adjuvant platform toward Phase 1 clinical trials, marking a significant step in its product development. The company aims to expand its market presence in North America, Europe, and Asia, seeking collaborations that will enhance its growth in these regions.

The anticipated advancements will support its goal of developing innovative vaccine solutions for global health challenges.